Telomere length and telomerase activity in the BCR-ABL-transformed murine Pro-B cell line BaF3 is unaffected by treatment with imatinib

Experimental Hematology

Volumn 33, Issue 5, 2005, Pages 542-549

  Hartmann, Ulrike ^a,e   Balabanov, Stefan ^a   Ziegler, Patrick ^a   Fellenberg, Jörg ^d   Van Der Kuip, Heiko ^b   Duyster, Justus ^c   Lipp, Hans Peter ^e   Bokemeyer, Carsten ^a   Kanz, Lothar ^a   Brümmendorf, Tim H ^a,f  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^f UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB; INTERLEUKIN 3; TELOMERASE;

ANIMAL CELL; ARTICLE; CELL DIVISION; CELL INTERACTION; CELL NUCLEUS MEMBRANE; CELL STRAIN; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; GENETIC TRANSFECTION; LEUKOCYTE MEMBRANE; LYMPHOCYTE CULTURE; LYMPHOCYTE TRANSFORMATION; MITOSIS INHIBITION; NONHUMAN; PRIORITY JOURNAL; PROMYELOCYTE; PROTEIN LOCALIZATION; TELOMERE;

EID: 20944447014     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2005.02.002     Document Type: Article

References (46)

1. S. Faderl, M. Talpaz, Z. Estrov, S. O'Brien, R. Kurzrock, and H.M. Kantarjian The biology of chronic myeloid leukemia N Engl J Med 341 1999 164 172
2. W.H. Raskind, and P.J. Fialkow The use of cell markers in the study of human hematopoietic neoplasia Adv Cancer Res 49 1987 127 167
3. J.D. Rowley Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and giemsa staining Nature 243 1973 290 293
4. J. Groffen, J.R. Stephenson, N. Heisterkamp, A. de Klein, C.R. Bartram, and G. Grosveld Philadelphia chromosomal breakpoints are clustered within a limited region, Bcr, on chromosome 22 Cell 36 1984 93 99
5. E. Shtivelman, B. Lifshitz, R.P. Gale, and E. Canaani Fused transcript of Abl and Bcr genes in chronic myelogenous leukaemia Nature 315 1985 550 554
6. J.V. Melo The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype Blood 88 1996 2375 2384
7. B.J. Druker, S. Tamura, and E. Buchdunger Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells Nat Med 2 1996 561 566
8. E. Buchdunger, J. Zimmermann, and H. Mett Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative Cancer Res 56 1996 100 104
9. K. Okuda, E. Weisberg, D.G. Gilliland, and J.D. Griffin ARG tyrosine kinase activity is inhibited by STI571 Blood 97 2001 2440 2448
10. E. Buchdunger, C.L. Cioffi, and N. Law Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by C-Kit and platelet-derived growth factor receptors J Pharmacol Exp Ther 295 2000 139 145
11. B.J. Druker, and N.B. Lydon Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia J Clin Invest 105 2000 3 7
12. B.J. Druker Imatinib alone and in combination for chronic myeloid leukemia Semin Hematol 40 2003 50 58
13. E.H. Blackburn Telomeres Trends Biochem Sci 16 1991 378 381
14. B. van Steensel, and T. de Lange Control of telomere length by the human telomeric protein TRF1 Nature 385 1997 740 743
15. B. van Steensel, A. Smogorzewska, and T. de Lange TRF2 protects human telomeres from end-to-end fusions Cell 92 1998 401 413
16. C.B. Harley, A.B. Futcher, and C.W. Greider Telomeres shorten during ageing of human fibroblasts Nature 345 1990 458 460
17. C.B. Harley, H. Vaziri, C.M. Counter, and R.C. Allsopp The telomere hypothesis of cellular aging Exp Gerontol 27 1992 375 382
18. D. Gisselsson, T. Jonson, and A. Petersen Telomere dysfunction triggers extensive DNA fragmentation and evolution of complex chromosome abnormalities in human malignant tumors Proc Natl Acad Sci U S A 98 2001 12683 12688
19. C.W. Greider Telomerase activity, cell proliferation, and cancer Proc Natl Acad Sci U S A 95 1998 90 92
20. T.H. Brummendorf, T.L. Holyoake, and N. Rufer Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leukemia measured by flow cytometry Blood 95 2000 1883 1890
21. T.H. Brummendorf, N. Rufer, and T.L. Holyoake Telomere length dynamics in normal individuals and in patients with hematopoietic stem cell-associated disorders Ann N Y Acad Sci 938 2001 293 303
22. K. Ohyashiki, J.H. Ohyashiki, H. Iwama, S. Hayashi, J.W. Shay, and K. Toyama Telomerase activity and cytogenetic changes in chronic myeloid leukemia with disease progression Leukemia 11 1997 190 194
23. M. Engelhardt, K. Mackenzie, P. Drullinsky, R.T. Silver, and M.A. Moore Telomerase activity and telomere length in acute and chronic leukemia, pre- and post-ex vivo culture Cancer Res 60 2000 610 617
24. K. Ohyashiki, H. Iwama, and T. Tauchi Telomere dynamics and genetic instability in disease progression of chronic myeloid leukemia Leuk Lymphoma 40 2000 49 56
25. T.H. Brummendorf, I. Ersoz, and U. Hartmann Normalization of previously shortened telomere length under treatment with imatinib argues against a preexisting telomere length deficit in normal hematopoietic stem cells from patients with chronic myeloid leukemia Ann N Y Acad Sci 996 2003 26 38
26. T.H. Brummendorf, I. Ersoz, and U. Hartmann Telomere length in peripheral blood granulocytes reflects response to treatment with imatinib in patients with chronic myeloid leukemia Blood 101 2003 375 376
27. G.Q. Daley, and D. Baltimore Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/Abl protein Proc Natl Acad Sci U S A 85 1988 9312 9316
28. P.R. Twentyman, N.E. Fox, and J.K. Rees Chemosensitivity testing of fresh leukaemia cells using the MTT colorimetric assay Br J Haematol 71 1989 19 24
29. R. Arnould, J. Dubois, and F. Abikhalil Comparison of two cytotoxicity assays - tetrazolium derivative reduction (MTT) and tritiated thymidine uptake - on three malignant mouse cell lines using chemotherapeutic agents and investigational drugs Anticancer Res 10 1990 145 154
30. T.C. Chou, and P. Talalay Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors Eur J Biochem 115 1981 207 216
31. T.C. Chou, and P. Talalay Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv Enzyme Regul 22 1984 27 55
32. I. Nicoletti, G. Migliorati, M.C. Pagliacci, F. Grignani, and C.A. Riccardi Rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry J Immunol Methods 139 1991 271 279
33. N. Rufer, T.H. Brummendorf, and S. Kolvraa Telomere fluorescence measurements in granulocytes and T lymphocyte subsets point to a high turnover of hematopoietic stem cells and memory T cells in early childhood J Exp Med 190 1999 157 167
34. N. Rufer, W. Dragowska, G. Thornbury, E. Roosnek, and P.M. Lansdorp Telomere length dynamics in human lymphocyte subpopulations measured by flow cytometry Nat Biotechnol 16 1998 743 747
35. G.M. Baerlocher, J. Mak, T. Tien, and P.M. Lansdorp Telomere length measurement by fluorescence in situ hybridization and flow cytometry: Tips and pitfalls Cytometry 47 2002 89 99
36. Y.Y. Wu, A.M. Hruszkewycz, and R.M. Delgado Limitations on the quantitative determination of telomerase activity by the electrophoretic and ELISA based TRAP assays Clin Chim Acta 293 2000 199 212
37. R. Gonzalez-Quevedo, C. de Juan, and M.J. Massa Detection of telomerase activity in human carcinomas using a trap-ELISA method: Correlation with hTR and hTERT expression Int J Oncol 16 2000 623 628
38. S. Kharbanda, V. Kumar, and S. Dhar Regulation of the hTERT telomerase catalytic subunit by the C-Abl tyrosine kinase Curr Biol 10 2000 568 575
39. T. Tauchi, A. Nakajima, and G. Sashida Inhibition of human telomerase enhances the effect of the tyrosine kinase inhibitor, imatinib, in BCR-ABL-positive leukemia cells Clin Cancer Res 8 2002 3341 3347
40. N. Carlesso, D.A. Frank, and J.D. Griffin Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl J Exp Med 183 1996 811 820
41. F. Gesbert, and J.D. Griffin Bcr/Abl activates transcription of the Bcl-X gene through STAT5 Blood 96 2000 2269 2276
42. H. van der Kuip, A.W. Goetz, C. Miething, J. Duyster, and W.E. Aulitzky Adhesion to fibronectin selectively protects Bcr-Abl+ cells from DNA damage-induced apoptosis Blood 98 2001 1532 1541
43. S. Dhut, T. Chaplin, and B.D. Young BCR-ABL and BCR proteins: Biochemical characterization and localization Leukemia 4 1990 745 750
44. C.L. Sawyers, J. McLaughlin, A. Goga, M. Havlik, and O. Witte The nuclear tyrosine kinase C-Abl negatively regulates cell growth Cell 77 1994 121 131
45. Y. Yang, Y. Chen, C. Zhang, H. Huang, and S.M. Weissman Nucleolar localization of HTERT protein is associated with telomerase function Exp Cell Res 277 2002 201 209
46. P. Vigneri, and J.Y. Wang Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase Nat Med 7 2001 228 234